Strides Arcolab Ltd. said it had received approval from the US FDA to market its generic Vancomycin Hydrochloride capsules in the strength of 125mg and 250 mg.
Vancomycin capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of last resort, used only after treatment with other antibiotics had failed.
The company plans to launch the product immediately through US-based Alvogen on a profit-sharing basis, the company said.
As per IMS health data, Vancomycin capsules had total US sales of $332 million for the twelve months ended February 12, with no prior generic approvals.
Commenting on the development, Strides Group CEO Arun Kumar said, "Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult-to-manufacture products.''
At the BSE, Strides Arcolab closed Wednesday's trading at Rs 631.90, after touching a 52-week high of Rs.649 in the early trading session.
Click here to receive FREE breaking news email alerts for Strides Arcolab Ltd. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com